Viral Specific T-cells for Treatment of COVID-19

Status Withdrawn

Clinical Trial Summary

The purpose of this research study is to learn more about the use of viral specific T-lymphocytes (VSTs) when given in the presence of COVID-19 signs and symptoms, caused by the virus SARS-CoV-2. VSTs are cells specially designed to fight viral infections. These cells are created from a blood sample collected from a donor who has recovered from COVID-19 infection. VSTs are investigational meaning that they are not approved by the Food and Drug Administration (FDA). COVID-19 is a new virus and treatment options are evolving rapidly. VSTs have been successfully used to treat many different viral infections and may be beneficial in treating COVID-19 in the absence of other treatments.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04406064
Study type	Interventional
Source	Children's Hospital Medical Center, Cincinnati
Contact
Status	Withdrawn
Phase	Phase 2
Start date	January 2021
Completion date	June 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05568953` - An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity	Phase 2
Not yet recruiting	`NCT05902702` - Isotonic Saline for Children With Bronchiolitis	N/A
Not yet recruiting	`NCT05953233` - School Inner City Air Study	N/A
Completed	`NCT01570283` - ARMS - Rapidly Generated Multivirus-Specific CTLs for Prophylaxis & Treatment of EBV, CMV, Adenovirus, HHV6 & BK Virus	Phase 1/Phase 2
Not yet recruiting	`NCT01159470` - The Rate of C-reactive Protein (CRP) Increase as a Marker for Bacterial Infections in Children	N/A
Recruiting	`NCT02532452` - Third Party Viral Specific T-cells (VSTs)	Phase 2
Recruiting	`NCT05246098` - REVIVe: Frailty, Rehabilitation, and Outcomes in Critically Ill Adult and Pediatric Survivors of COVID-19 or ARI
Recruiting	`NCT05603650` - Effects of Mouthrinses on the Microbiome of the Oral Cavity and GI Tract	N/A
Completed	`NCT04525456` - Immune Responses With Reduxium	N/A
Completed	`NCT04643678` - Anakinra in the Management of COVID-19 Infection	Phase 2/Phase 3
Completed	`NCT03189537` - Study of Post-Exposure Ingavirin® Prophylaxis of Influenza and Acute Respiratory Viral Infections	Phase 3
Completed	`NCT04267809` - Modulate Cellular Stress in the Immune Cells to Reduce Rate of Symptomatic Viral Infection	Phase 2
Completed	`NCT00341081` - Validation of Self-Reported Needle Sharing Among Injection Drug Users	N/A
Recruiting	`NCT04088916` - Proviral DNA as a Target for HIV-1 Resistance Analysis
Terminated	`NCT04401410` - Anti-SARS Cov-2 T Cell Infusions for COVID 19	Phase 1
Terminated	`NCT00952185` - Influenza Vaccine in Preventing Flu in Patients Who Have Undergone Stem Cell Transplant and in Healthy Volunteers	N/A
Recruiting	`NCT06149494` - RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection	Phase 2
Active, not recruiting	`NCT04254991` - A Controlled, Blinded Study to Validate the Diagnostic Accuracy and Assess the Clinical Utility of a Host-response Based Diagnostic Tool for Distinguishing Between Bacterial and Viral Etiologies in Pediatric Patients Presenting to the ED With Suspicion of Acute Infection
Completed	`NCT05897801` - Distinguishing Bacterial and Viral Infections by MeMed BV® Test to Limit Gut Colonization by MDRO
Terminated	`NCT02696291` - Safety and Pharmacokinetics of UV-4B Solution Administered Orally as Multiple Ascending Doses to Healthy Subjects	Phase 1